The efficacy of Levodopa+DDC inhibitor+Entacapone versus Levodopa+DDC inhibitor+Placebo in Parkinson's disease: an intervention review

Jennifer Harrison

Abstract


Parkinson's disease (PD) has many possible treatment options. The main therapy uses a drug called levodopa. However after prolonged use, this drug begins to wear off and becomes less effective. Therefore additional drugs are needed to help ensure the patient is comfortable and to aid the relief of symptoms that can often occur. The addition of the COMT inhibitor, entacapone, aims to reduce motor symptoms and smooth out fluctuations that can sometimes be experienced with levodopa therapy. These can include bradykinesia, which is slowness of movement and help to control the resting tremor that is often associated with PD. The aim of this review is to determine if adding entacapone to existing levodopa therapy helps to improve patients motor symptoms and improve their ability to carry out every day activities; these outcomes will be measured using the unified Parkinson's disease rating scale UPDRS. 


Full Text:

PDF

References


Included studies

Brooks 2003

D J Brooks, H Sagar, and the UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. Journal of Neurology, Neurosurgery, and Psychiatry 2003;74:1071-1079.

Hauser 2009

Hauser Robert A, Panisset Michel, Abbruzzese Giovanni, Mancione Linda, Dronamraju Nalina, Kakarieka Algirdas. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Movement Disorder Society 2009;24(4):541-50.

Myllylä 2001

Myllylä V V, Kultalahti E-R, Haapaniemi H, Leinonen M, FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson’s disease. European Journal of Neurology 2001;8(1):53-60.

Olanow 2004

Olanow C W, Kieburtz K, Stern M, Watts R, Langston J W, Guarnieri M, Hubble J, US01 Study Team. Double-blind, Placebo-Controlled Study of Entacapone in Levodopa-Treated Patients With Stable Parkinson Disease. Archive of Neurology October 2004;61:1563-1568.

Poewe 2002

Poewe W H, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomised placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurologica Scandinvica 2002;105:245-255.

Rinne 1998

Rinne U K, Larsen J P, Siden A, Worm-Peterson, Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. The American Academy of Neurology 1998;51:1309-1314.

Stocchi 2010

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang E, Olanow W. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. American Neurological Association 2010;68:18-27.

Tolosa 2013

Tolosa E, Hernandez B, Linazasoro G, Lopez-Lozano J, Mir P, Marey J, Kulisevsky J. Efficacy of Levodopa/Cabidopa/ Entacapone versus Levodopa/Carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind. Journal of Neural Transmission November 2013;[epub ahead of print]:1435-1463.

Excluded studies

Bet 2008

Beta L, Bareggib S R, Paceia F, Bondiolottib G, Meolaa G, Schapirac A H V. Bimodal administration of entacapone in Parkinson’s disease patients improves motor control. European Journal of Neurology 2008;15:268–273.

Durif 2001

Durif F, Devaux I, Pere J J, Delumeau J C, Bourdeix I, on behalf of the F-01 Study Group. Efficacy and tolerability of Entacapone as adjunctive therapy to Levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: An open multicentre study. European Neurology 2001;45:111-118.

Gershanik 2003

Gershanika O, Emreb M, Bernhardc G, Sauer D. Efficacy and safety of levodopa with entacapone in Parkinson’s disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2003;17:963-971.

Kieburtz 1997

Kiburtz K, Shoulson I, Fahn S, McDermott M, Koller W, Nutt J, (Parkinson's Study Group). Entacapone improves motor fluctuations is Levodopa treated Parkinson's Disease patients. American Neurological Association 1997;42:747-755.

Larsen 2003

Larsen J P, Worm-Petersen J, Sidén Å, Gordin A, Reinikainen K, Leinonen M, NOMESAFE study group. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. European Journal of Neurology 2003;10(2):137-46.

Mizuno 2007

Mizuno Y, Kanazawa I, Kuno S, Yanagisawa N, Yamamoto M, Kondo T, Japanese Parkinson–Entacapone Study Group. Placebo-Controlled, Double-Blind Dose-Finding Study of Entacapone in Fluctuating Parkinsonian Patients. Movement Disorders 2007;22(1):75-80.

Olanow 2013

Olanow C D, Kieburtz K, Rascol O, Poewe W, Schapira A H, Nissinen H, Leinonen M, Stocchi F,. Factors Predictive of the Development of Levodopa-Induced Dyskinesia and Wearing-Off in Parkinson’s Disease. Movement Disorders 2013;28(8):1064-1071.

Piccini 2000

Piccini P, Brooks D J, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (COMT)inhibitor entacapone enhances the pharmacokinetic and clinical response to SinemetCR in Parkinson’s disease. Journal of Neurology Neurosurgery and Psychiatry 2000;68:589–594.

Reichmann 2005

Reichmann H, Boas J, MacMahon D, Myllyla V, Hakala A, Reinikainen K, ComQol Study Group. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurologica Scandinvica 2005;111(1):21-8.

Additional references

Braga 2014

M Braga, M Pederzoli, A Antonini, F Beretta, V Crespi. Reasons for hospitalisation in Parkinson's disease: A case-control study. Parkinsonism & Related Disorders Feb 2014;http://dx.doi.org/10.1016/j.parkreldis.2014.01.022([only available online as so recent, will be published in the journal very soon, hence no page/volume/issue number]).

Bugamelli 2011

F Bugamelli, C Marcheselli, E Barba, M A Raggi. Determination of l-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC–ED. Journal of Pharmaceutical and Biomedical Analysis Feb 2011;54(3):562–567.

Chen 2007

Chen J, Fernandez H. Community and Long-Term Care Management of Parkinson's Disease in the Elderly. Drugs Aging 2007;24(8):663-680.

Fahn 2000

Fahn S. Review: The spectrum of levodopa-induced dyskinesias. Annals of neurology April 2000;47:9-11.

Ford 2010

Ford Matthew P, Malone Laurie A, Nyikos Ildiko, Yelisetty Rama, Bickel C Scott. Gait Training With Progressive External Auditory Cueing in Persons With Parkinson's Disease. Archives of Physical Medicine and Rehabilitation 2010;91(8):1255-1265.

Goetz 2008

Goetz, Christopher G., Tilley, Barbara C., Shaftman, Stephanie R., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results.. Movement Disorders Volume 15 November 2008;23(15):2129–2170.

Goldacre 2012

Ben Goldacre. Bad Pharma. Hammersmith, London: Harper Collins Publishers, 2012.

Heikknen 2002

Helena Heikkinen, Anu Varhe, Tarmo Laine, Jaakko Puttonen, Marjo Kela, Seppo Kaakkola. Entacapone improves the availability of l-dopa in plasma by decreasing its peripheral metabolism independent of l-dopa/carbidopa dose. British Journal of Clinical Pharmacology October 2002; 54(4):363–371.

Hickey 2011

Hickey, Patrick; Stacy, Mark. Available and emerging treatments for Parkinson's disease: A review. Journal of Drug Design, Development and Therapy May 2011; 5:241-254.

Korczyn 2010

Korczyn Amos D, Gurevich Tanya. Parkinson's disease: Before the motor symptoms and beyond. Journal of the Neurological Sciences 2010; 289(1):2-6.

Lee 2002

M Lee, H Kim, E Cho, J Lim, J Rinne. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson’s disease. Neurology 2002; 58(4):564-567.

Linazasoro 2008

Linazasoro G. Potential applications of nanotechnologies to Parkinson's disease therapy.. Parkinsonism Related Disorders 2008; 15(5):383-392.

Lo 2007

Lo K, Leung K, Shek A. Management of Parkinson's disease: Current treatments, recent advances, and future developments. Formulary 2007;42:529-544.

Maranis 2011

Maranis S, Tsouli S, Konitstiotis S. Treatment of motor symptoms in advanced Parkinson's disease: A practical approach. Progress in Neuro-Psychophamacology and Biological Psychiatry 2011;35:1795-1807.

Marin 2008

Marin C, Aguilara E, Mengod G, Cortés R, Rodríguez-Oroz M C, Obesoc J A. Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes. Neurobiology of Disease December 2008;32(3):340-348.

Sheridan 2012

Sherican M, Gillian H, Keating M. Rasagiline: A review of its use in the treatment of idiopathic Parkinson's disease. Drug 2012; 72(5):643-669.

Singh 2007

Singh N, Pillay V, Choonara Y. Advances in the treatment of Parkinson's disease. Progress in Neurobiology 2007; 81:29-44.

Stacy 2009

Stacy M. Medical treatment of Parkinson's disease. Clinical Neurology and Neurosurgery August 2009; 27(3):605-631.

Tai 2002

Tai,Chun-Hui; Wu, Ruey-Meei. Catechol-O-Methyltransferase and Parkinson's disease. Acta Medica Okayama 2002; 56(1):1-6.

Williams 2010

Ruth Williams. Slowing the decline. Nature August 2010; 466:13-14.


Refbacks

  • There are currently no refbacks.


Creative Commons License 
This work is licensed under a Creative Commons Attribution 3.0 License

ISSN 1754-2383 [Online] ©University of Plymouth